Ryan Liabenow
The economic and professional appeal of DPC has caused it to spread to at least 24 states. Scalable models are being developed and increasingly attract investor dollars.
The growth of generic drugs has been a good news story for payers and pharmaceutical benefit managers (PBMs), but that story may be coming to an end.
While certain key generic drugs will take billions in drug costs out of the healthcare system in the next 3 to 4 years, this anticipated decline in spending is masking the growth of specialty drug costs.
This blog post was removed at the request of the author. Please see his other blogs here: http://www.healthcarefinancenews.com/blog/author/2326.